An Open Label Biomarker Pilot Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer
This is a biomarker study designed to test the preclinically generated hypothesis of anti-tumoral activity of denosumab in patients with early breast cancer candidates a tumour excision
Indication: Breast Neoplasm Female
Modality: small molecule
Target: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Sponsor: Institut Català d'Oncologia
Source URL: ClinicalTrials.gov
Source updated: Nov 03, 2021
Ingested: Jun 19, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
View original source fields
Condition raw: Breast Neoplasm Female, Stage I Breast Cancer, Stage II Breast Cancer, Hormone Receptor Negative Neoplasm, Hormone Receptor Positive Tumor
Condition normalized: Breast Neoplasm Female, Stage I Breast Cancer, Stage II Breast Cancer, Hormone Receptor Negative Neoplasm, Hormone Receptor Positive Tumor
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Target normalized: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]